Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.74 Insider Own1.51% Shs Outstand192.74M Perf Week-13.93%
Market Cap202.38M Forward P/E- EPS next Y-1.15 Insider Trans-1.06% Shs Float189.84M Perf Month15.31%
Income-91.17M PEG- EPS next Q-0.42 Inst Own54.76% Short Float16.18% Perf Quarter10.18%
Sales21.73M P/S9.31 EPS this Y9.42% Inst Trans7.50% Short Ratio4.83 Perf Half Y-24.46%
Book/sh2.08 P/B0.50 EPS next Y27.68% ROA-16.08% Short Interest30.71M Perf Year-71.39%
Cash/sh0.95 P/C1.10 EPS next 5Y45.80% ROE-47.81% 52W Range0.85 - 5.53 Perf YTD-23.91%
Dividend Est.- P/FCF- EPS past 5Y- ROI-20.06% 52W High-81.01% Beta0.83
Dividend TTM- Quick Ratio1.42 Sales past 5Y120.04% Gross Margin-15.86% 52W Low24.26% ATR (14)0.10
Dividend Ex-Date- Current Ratio1.55 EPS Y/Y TTM87.79% Oper. Margin-1523.91% RSI (14)49.51 Volatility12.42% 9.19%
Employees- Debt/Eq1.36 Sales Y/Y TTM322.60% Profit Margin-419.62% Recom2.64 Target Price4.12
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q29.93% Payout- Rel Volume0.63 Prev Close1.15
Sales Surprise-3.44% EPS Surprise1.65% Sales Q/Q17353.52% EarningsMay 09 BMO Avg Volume6.36M Price1.05
SMA201.63% SMA504.83% SMA200-39.55% Trades Volume3,978,060 Change-8.70%
Date Action Analyst Rating Change Price Target Change
Dec-11-23Downgrade HSBC Securities Hold → Reduce
Dec-08-23Upgrade Morgan Stanley Underweight → Equal-Weight $3 → $7
Oct-17-23Initiated Cantor Fitzgerald Neutral
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Jul-03-24 04:05PM
Jun-17-24 03:27PM
Jun-02-24 10:15PM
May-29-24 07:00AM
May-17-24 03:46PM
09:22AM Loading…
May-16-24 09:22AM
May-14-24 11:24AM
May-10-24 03:36PM
May-09-24 07:00AM
May-07-24 12:40PM
May-06-24 07:05AM
Apr-26-24 04:43PM
02:05PM Loading…
Apr-16-24 02:05PM
Apr-15-24 08:15AM
Apr-13-24 04:22PM
Apr-11-24 08:30AM
Apr-02-24 11:33AM
Mar-29-24 05:20AM
Mar-27-24 11:37AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
Mar-18-24 06:05PM
Mar-13-24 07:50AM
08:00AM Loading…
Mar-11-24 08:00AM
Mar-05-24 06:56PM
Jan-27-24 07:28AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
Dec-07-23 11:30AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
Nov-08-23 03:39PM
Nov-07-23 05:18PM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klima Thomas JSee RemarksJun 03 '24Sale0.973,8343,726121,006Jun 04 04:22 PM
Obenshain AndrewPresident and CEOMar 04 '24Sale1.536,0959,311279,998Mar 05 05:40 PM
Klima Thomas JSee RemarksMar 04 '24Sale1.534,5736,986124,840Mar 05 05:39 PM
Colvin Richard AChief Medical OfficerMar 01 '24Sale1.536,77010,342118,368Mar 05 05:40 PM
Vittiglio JosephChief Business & Legal OfficerFeb 05 '24Sale0.905,2174,70844,783Feb 06 04:07 PM
Klima Thomas JSee RemarksFeb 05 '24Sale0.902,7142,449129,413Feb 06 04:07 PM
Obenshain AndrewPresident and CEOFeb 05 '24Sale0.901,8791,696286,093Feb 06 04:07 PM
Obenshain AndrewPresident and CEOJan 05 '24Sale1.433,1624,520287,972Jan 09 04:05 PM
Colvin Richard AChief Medical OfficerJan 05 '24Sale1.42597845125,138Jan 09 04:05 PM
Krawtschuk ChristopherChief Financial OfficerDec 06 '23Sale4.524,52620,43745,474Dec 08 04:42 PM
Obenshain AndrewPresident and CEONov 03 '23Sale3.178072,555291,134Nov 03 04:10 PM
Colvin Richard AChief Medical OfficerNov 02 '23Sale2.982,3436,975125,735Nov 03 04:10 PM
Klima Thomas JSee RemarksSep 05 '23Sale3.799223,493132,127Sep 06 04:30 PM
Obenshain AndrewPresident and CEOAug 10 '23Sale3.5416,92959,956291,941Aug 10 05:00 PM